You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameScopolamine
Accession NumberDB00747  (APRD00616)
TypeSmall Molecule
GroupsApproved
DescriptionAn alkaloid from Solanaceae, especially Datura metel L. and Scopola carniolica. Scopolamine and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. Among the many uses are as an anesthetic premedication, in urinary incontinence, in motion sickness, as an antispasmodic, and as a mydriatic and cycloplegic. [PubChem]
Structure
Thumb
Synonyms
(-)-hyoscine
(-)-scopolamine
(1S,3S,5R,6R,7S)-6,7-Epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate
6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate
6,7-Epoxytropine tropate
alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
Hyoscine
scopine (-)-tropate
scopine (−)-tropate
Scopolamine hydrobromide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Scopolamine Hydrobromide InjectionLiquid0.4 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories Ltd2008-05-31Not applicableCanada
Scopolamine Hydrobromide InjectionLiquid0.6 mgIntramuscular; Intravenous; SubcutaneousOmega Laboratories Ltd2008-07-08Not applicableCanada
Scopolamine Hydrobromide Injection 0.4mg/mlSolution.4 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1981-12-31Not applicableCanada
Scopolamine Hydrobromide Injection 0.6mg/mlSolution.6 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1981-12-31Not applicableCanada
Transderm ScopPatch, extended release1 mg/3dTransdermalNovatris Consumer Health, Inc.2007-10-02Not applicableUs
Transderm ScopPatch, extended release1 mg/3dTransdermalBaxter Healthcare Corporation2003-01-01Not applicableUs
Transderm ScopPatch, extended release1 mg/3dTransdermalPhysicians Total Care, Inc.2007-10-02Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Scopolamine HydrobromideInjection, solution.4 mg/mLIntramuscular; Intravenous; SubcutaneousAPP Pharmaceuticals, LLC2000-10-18Not applicableUs
International Brands
NameCompany
ScopodermNot Available
Transderm-ScopNovartis
Brand mixtures
NameLabellerIngredients
Atenolol ScopolamineTps
B-donnaWinder Laboratories, LLC
Belladonna Alkaloids With PhenobartbitalLiberty Pharmaceuticals, Inc.
Diban CapAyerst Laboratories
Donnagel LiqAyerst Laboratories
DonnatalRebel Distributors Corp
Donnatal ElixirAyerst Laboratories
Donnatal ExtentabsPBM Pharmaceuticals, Inc
Donnatal Extentabs SrtWyeth Ayerst Canada Inc.
Donnatal TabWyeth Ayerst Canada Inc.
Me-PB-hyosMethod Pharmaceuticals, Llc
PhenohytroWinder Laboratories, LLC
Propranolol ScopolamineTps
QuadrapaxRebel Distributors Corp
Re-PB Hyos ElixirKAISER FOUNDATION HOSPITALS
Se-donna Pb HyosSeton Pharmaceuticals
SaltsNot Available
Categories
UNIIDL48G20X8X
CAS number51-34-3
WeightAverage: 303.3529
Monoisotopic: 303.147058165
Chemical FormulaC17H21NO4
InChI KeySTECJAGHUSJQJN-FWXGHANASA-N
InChI
InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13-,14+,15-,16+/m1/s1
IUPAC Name
(1R,2R,4S,5S,7R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0²,⁴]nonan-7-yl (2S)-3-hydroxy-2-phenylpropanoate
SMILES
CN1[[email protected]]2C[C@@H](C[C@@H]1[[email protected]]1O[C@@H]21)OC(=O)[[email protected]](CO)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness.
Structured Indications
PharmacodynamicsScopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Scopolamine has many uses including the prevention of motion sickness. It is not clear how Scopolamine prevents nausea and vomiting due to motion sickness. The vestibular part of the ear is very important for balance. When a person becomes disoriented due to motion, the vestibule sends a signal through nerves to the vomiting center in the brain, and vomiting occurs. Acetylcholine is a chemical that nerves use to transmit messages to each other. It is believe that Scopolamine prevents communication between the nerves of the vestibule and the vomiting center in the brain by blocking the action of acetylcholine. Scopolamine also may work directly on the vomiting center. Scopolamine must be taken before the onset of motion sickness to be effective.
Mechanism of actionScopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center).
TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M1Proteinyes
antagonist
HumanP11229 details
Sucrase-isomaltase, intestinalProteinunknown
inhibitor
HumanP14410 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinunknown
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinunknown
antagonist
HumanP08912 details
Related Articles
AbsorptionBioavailability is 10 - 50%
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationLess than 10% of the total dose is excreted in the urine as parent and metabolites over 108 hours.
Half life4.5 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Scopolamine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Scopolamine.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Scopolamine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Scopolamine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Scopolamine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Scopolamine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Scopolamine.Approved, Vet Approved
AclidiniumAclidinium may increase the anticholinergic activities of Scopolamine.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Scopolamine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Scopolamine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Scopolamine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Scopolamine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Scopolamine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Scopolamine.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Scopolamine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Scopolamine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Scopolamine.Approved, Illicit, Investigational
AmbenoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Ambenonium.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Scopolamine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Scopolamine.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Scopolamine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Scopolamine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Scopolamine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Scopolamine.Experimental
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Scopolamine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Scopolamine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Scopolamine.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Scopolamine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Scopolamine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Scopolamine.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Scopolamine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Scopolamine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Scopolamine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Scopolamine.Approved, Vet Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Scopolamine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Scopolamine.Vet Approved
AzelastineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Scopolamine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Scopolamine.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine.Approved
BenperidolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Scopolamine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Scopolamine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Scopolamine.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Scopolamine.Approved, Vet Approved
BezitramideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Scopolamine is combined with Biperiden.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Scopolamine.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Scopolamine.Approved
Botulinum Toxin Type AScopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BScopolamine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Scopolamine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Scopolamine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Scopolamine.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Scopolamine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Scopolamine.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Scopolamine.Approved, Investigational
BuprenorphineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Scopolamine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Scopolamine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Scopolamine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Scopolamine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Scopolamine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Scopolamine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Scopolamine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Scopolamine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Scopolamine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Scopolamine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Scopolamine.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Scopolamine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Scopolamine.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Scopolamine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Scopolamine.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Scopolamine.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Scopolamine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Scopolamine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Scopolamine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Scopolamine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Scopolamine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Scopolamine.Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Scopolamine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Scopolamine.Approved, Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Scopolamine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Scopolamine.Approved
CimetropiumScopolamine may increase the anticholinergic activities of Cimetropium.Experimental
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Scopolamine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Scopolamine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Scopolamine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Scopolamine.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Scopolamine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Scopolamine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Scopolamine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Scopolamine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Scopolamine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Scopolamine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Scopolamine.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Scopolamine.Approved, Illicit
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Scopolamine.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Scopolamine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Scopolamine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Scopolamine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Scopolamine.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Scopolamine.Approved
CoumaphosThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Scopolamine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Scopolamine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclopentolate.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Scopolamine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Scopolamine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Scopolamine.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Scopolamine.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Scopolamine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Scopolamine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Scopolamine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Scopolamine.Approved, Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Scopolamine.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Scopolamine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Scopolamine.Approved
DecamethoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Demecarium.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Scopolamine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Scopolamine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Scopolamine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Scopolamine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Scopolamine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dexetimide.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Scopolamine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Scopolamine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Scopolamine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Scopolamine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Scopolamine.Approved, Illicit, Vet Approved
DichlorvosThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dicyclomine.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Scopolamine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Scopolamine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Scopolamine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Scopolamine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Scopolamine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Scopolamine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Scopolamine.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Scopolamine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Scopolamine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Scopolamine.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Scopolamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Scopolamine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Scopolamine.Approved, Investigational, Vet Approved
DonepezilThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Scopolamine.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Scopolamine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Scopolamine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Scopolamine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Scopolamine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Scopolamine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Scopolamine.Experimental
EchothiophateThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Echothiophate.Approved
EcopipamThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Scopolamine.Approved
EdrophoniumThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Scopolamine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Scopolamine.Approved, Investigational
EluxadolineScopolamine may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Scopolamine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Scopolamine.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Scopolamine.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Scopolamine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Scopolamine.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Scopolamine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Scopolamine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Scopolamine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Scopolamine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Scopolamine.Approved
EthanolScopolamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Scopolamine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Scopolamine.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Scopolamine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Scopolamine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Scopolamine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Scopolamine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Scopolamine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Scopolamine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Scopolamine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Scopolamine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Scopolamine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Scopolamine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Scopolamine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Scopolamine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Scopolamine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Scopolamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Scopolamine.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Scopolamine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Scopolamine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Scopolamine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Scopolamine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Scopolamine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Scopolamine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Scopolamine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Scopolamine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Scopolamine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Scopolamine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Scopolamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Scopolamine.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Scopolamine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Scopolamine is combined with gabapentin enacarbil.Approved
GalantamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Scopolamine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Scopolamine.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Scopolamine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Scopolamine.Approved
GepironeThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gepirone.Investigational
Ginkgo bilobaThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Scopolamine is combined with Glucagon recombinant.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Scopolamine.Approved, Illicit
GlycopyrroniumScopolamine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Scopolamine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Scopolamine.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Scopolamine.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Scopolamine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Scopolamine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Scopolamine.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Scopolamine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine.Approved, Vet Approved
HydrocodoneScopolamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Scopolamine.Approved, Vet Approved
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Scopolamine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Scopolamine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Scopolamine.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Scopolamine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Scopolamine.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Scopolamine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Scopolamine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Scopolamine.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Scopolamine.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Scopolamine.Approved, Investigational
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Scopolamine.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Scopolamine.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Scopolamine.Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Scopolamine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Scopolamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Scopolamine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Scopolamine.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Scopolamine.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Scopolamine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Scopolamine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Scopolamine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Scopolamine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Scopolamine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Scopolamine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Scopolamine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Scopolamine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Scopolamine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Scopolamine.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Scopolamine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Scopolamine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Scopolamine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Scopolamine.Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Scopolamine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Scopolamine.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Scopolamine.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Scopolamine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Scopolamine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Scopolamine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Scopolamine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Scopolamine.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Scopolamine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Vet Approved
MalathionThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Malathion.Approved, Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Scopolamine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Scopolamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Scopolamine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Scopolamine.Vet Approved
MefloquineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Scopolamine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Scopolamine.Approved
MemantineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Memantine.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Scopolamine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Scopolamine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Scopolamine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Scopolamine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Scopolamine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Scopolamine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methantheline.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Scopolamine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Scopolamine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Scopolamine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Scopolamine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Scopolamine.Approved
MethotrimeprazineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Scopolamine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methsuximide.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Scopolamine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Scopolamine.Approved, Vet Approved
MetixeneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Scopolamine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Scopolamine.Approved, Investigational
MetyrosineScopolamine may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the anticholinergic activities of Scopolamine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Scopolamine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Scopolamine is combined with Milnacipran.Approved
MinaprineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mirabegron.Approved
MirtazapineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Scopolamine.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Scopolamine.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Scopolamine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Scopolamine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Scopolamine is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Scopolamine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Scopolamine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Scopolamine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Scopolamine.Approved, Vet Approved
NefazodoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Scopolamine.Approved
NeostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Scopolamine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Scopolamine.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Scopolamine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Scopolamine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Scopolamine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Scopolamine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Scopolamine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Scopolamine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Scopolamine.Approved
NVA237The risk or severity of adverse effects can be increased when Scopolamine is combined with NVA237.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Scopolamine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Scopolamine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Scopolamine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Scopolamine.Approved, Illicit
OrphenadrineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Scopolamine.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Scopolamine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Scopolamine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Scopolamine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Scopolamine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Scopolamine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Scopolamine.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Scopolamine.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Scopolamine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Scopolamine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pancuronium.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Scopolamine.Approved, Investigational
ParaldehydeScopolamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Scopolamine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Scopolamine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Scopolamine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Scopolamine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Scopolamine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Scopolamine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Scopolamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Scopolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Scopolamine.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Physostigmine.Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Scopolamine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Scopolamine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Scopolamine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Scopolamine.Approved
PizotifenThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pizotifen.Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Scopolamine.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Scopolamine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Scopolamine.Approved
Potassium ChlorideScopolamine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramipexoleScopolamine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintidePramlintide may increase the anticholinergic activities of Scopolamine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Scopolamine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Scopolamine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Scopolamine.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Scopolamine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Scopolamine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Scopolamine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Scopolamine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Scopolamine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Scopolamine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Scopolamine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Scopolamine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Scopolamine.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Scopolamine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Scopolamine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propantheline.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Scopolamine.Approved, Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Scopolamine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Scopolamine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Scopolamine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Scopolamine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Scopolamine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Scopolamine.Investigational
PyridostigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Pyridostigmine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Scopolamine.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Scopolamine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Scopolamine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Scopolamine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ramelteon.Approved, Investigational
RamosetronScopolamine may increase the constipating activities of Ramosetron.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Scopolamine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Scopolamine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Scopolamine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Scopolamine.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Scopolamine.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Scopolamine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Scopolamine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Scopolamine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Scopolamine.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Scopolamine.Approved
RivastigmineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Scopolamine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Scopolamine.Vet Approved
RopiniroleScopolamine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Scopolamine.Approved
RotigotineScopolamine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Scopolamine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Scopolamine.Experimental
Sage 547The risk or severity of adverse effects can be increased when Scopolamine is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Scopolamine.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Scopolamine.Approved, Investigational
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Scopolamine butylbromide.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Scopolamine.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Scopolamine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Scopolamine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Scopolamine.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Scopolamine.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Scopolamine.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Scopolamine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Scopolamine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Solifenacin.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Scopolamine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Scopolamine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Scopolamine.Experimental
StiripentolThe risk or severity of adverse effects can be increased when Scopolamine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Scopolamine.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Scopolamine.Approved
SuvorexantScopolamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Tacrine.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Scopolamine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Scopolamine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Scopolamine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Scopolamine.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Scopolamine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Scopolamine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Scopolamine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Scopolamine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Scopolamine.Investigational
ThalidomideScopolamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Scopolamine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Scopolamine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Scopolamine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Scopolamine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Scopolamine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Scopolamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Scopolamine.Approved
TiotropiumScopolamine may increase the anticholinergic activities of Tiotropium.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Scopolamine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Scopolamine.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tolterodine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Scopolamine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Scopolamine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Scopolamine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Scopolamine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Scopolamine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Scopolamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Scopolamine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Scopolamine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Scopolamine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Scopolamine.Approved
TrichlorfonThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Scopolamine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Scopolamine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Scopolamine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Scopolamine is combined with Trimethaphan.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Scopolamine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Scopolamine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tropicamide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Scopolamine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tubocurarine.Approved
Uc1010The risk or severity of adverse effects can be increased when Scopolamine is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Scopolamine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Scopolamine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Scopolamine.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vecuronium.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Scopolamine.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Scopolamine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Scopolamine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vigabatrin.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Scopolamine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Scopolamine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Scopolamine.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Scopolamine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Scopolamine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Scopolamine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Scopolamine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Scopolamine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Scopolamine.Vet Approved
ZolpidemScopolamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Scopolamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Scopolamine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Scopolamine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Yang Guodong, “Preparation and application of scopolamine and chlorpromazine as a drug-withdrawal agent.” U.S. Patent US5543407, issued February, 1993.

US5543407
General References
  1. Putcha L, Cintron NM, Tsui J, Vanderploeg JM, Kramer WG: Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. Pharm Res. 1989 Jun;6(6):481-5. [PubMed:2762223 ]
External Links
ATC CodesS01FA02A04AD01N05CM05A04AD51
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelDownload (686 KB)
MSDSDownload (73.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9615
Blood Brain Barrier+0.8218
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5174
P-glycoprotein inhibitor INon-inhibitor0.87
P-glycoprotein inhibitor IINon-inhibitor0.8623
Renal organic cation transporterInhibitor0.531
CYP450 2C9 substrateNon-substrate0.7002
CYP450 2D6 substrateNon-substrate0.7296
CYP450 3A4 substrateSubstrate0.5253
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.927
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9581
BiodegradationNot ready biodegradable0.9073
Rat acute toxicity2.0907 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9378
hERG inhibition (predictor II)Non-inhibitor0.9167
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boca pharmacal inc
  • Private formulations inc
Packagers
Dosage forms
FormRouteStrength
TabletBuccal; Oral; Sublingual; Transmucosal
TabletOral
CapsuleOral
LiquidOral
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
ElixirOral
Injection, solutionIntramuscular; Intravenous; Subcutaneous.4 mg/mL
LiquidIntramuscular; Intravenous; Subcutaneous0.4 mg
LiquidIntramuscular; Intravenous; Subcutaneous0.6 mg
SolutionIntramuscular; Intravenous; Subcutaneous.4 mg
SolutionIntramuscular; Intravenous; Subcutaneous.6 mg
Patch, extended releaseTransdermal1 mg/3d
Prices
Unit descriptionCostUnit
Oscion Cleanser 6% Lotion 340.2 gm Bottle88.56USD bottle
Oscion Cleanser 3% Lotion 340.2 gm Bottle85.69USD bottle
Isopto Hyoscine 0.25% Solution 5ml Bottle30.99USD bottle
Transderm-Scop 1.5 mg (1 Box Contains 4 Patches)14.87USD patch
Transderm-Scop 1.5 mg (1 Box Contains 10 Patches)12.04USD patch
Transderm-scop 1.5 mg/72hr12.01USD each
Scopolamine hbr crystals6.86USD g
Isopto hyoscine 0.25% drops5.59USD ml
Scopolamine 0.4 mg/ml vial5.4USD ml
Buscopan 20 mg/ml4.5USD ml
Pamine forte 5 mg tablet3.9USD tablet
Pamine 2.5 mg tablet2.66USD tablet
Methscopolamine Bromide 5 mg tablet2.17USD tablet
Methscopolamine brom 5 mg tablet2.09USD tablet
Methscopolamine Bromide 2.5 mg tablet1.67USD tablet
Methscopolamine brom 2.5 mg tablet1.61USD tablet
Scopace 0.4 mg tablet0.67USD tablet
Buscopan 10 mg Tablet0.34USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point59 °CPhysProp
water solubility1E+005 mg/LYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.98SANGSTER (1994)
Caco2 permeability-4.93ADME Research, USCD
pKa7.75 (at 25 °C)SANGSTER,J (1994)
Predicted Properties
PropertyValueSource
Water Solubility6.61 mg/mLALOGPS
logP1.4ALOGPS
logP0.89ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)6.95ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area62.3 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity79.72 m3·mol-1ChemAxon
Polarizability31.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetic acid derivatives
Direct ParentPhenylacetic acid derivatives
Alternative Parents
Substituents
  • Phenylacetate
  • Beta-hydroxy acid
  • N-alkylpyrrolidine
  • Piperidine
  • Oxazinane
  • Morpholine
  • Hydroxy acid
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Oxirane
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Murasaki O, Kaibara M, Nagase Y, Mitarai S, Doi Y, Sumikawa K, Taniyama K: Site of action of the general anesthetic propofol in muscarinic M1 receptor-mediated signal transduction. J Pharmacol Exp Ther. 2003 Dec;307(3):995-1000. Epub 2003 Oct 8. [PubMed:14534362 ]
  2. Klinkenberg I, Blokland A: The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev. 2010 Jul;34(8):1307-50. doi: 10.1016/j.neubiorev.2010.04.001. Epub 2010 Apr 14. [PubMed:20398692 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sucrose alpha-glucosidase activity
Specific Function:
Plays an important role in the final stage of carbohydrate digestion. Isomaltase activity is specific for both alpha-1,4- and alpha-1,6-oligosaccharides.
Gene Name:
SI
Uniprot ID:
P14410
Molecular Weight:
209451.49 Da
References
  1. Minai-Tehrani D, Fooladi N, Minoui S, Sobhani-Damavandifar Z, Aavani T, Heydarzadeh S, Attar F, Ghaffari M, Nazem H: Structural changes and inhibition of sucrase after binding of scopolamine. Eur J Pharmacol. 2010 Jun 10;635(1-3):23-6. doi: 10.1016/j.ejphar.2010.02.040. Epub 2010 Mar 15. [PubMed:20230815 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Johnson DE, Nedza FM, Spracklin DK, Ward KM, Schmidt AW, Iredale PA, Godek DM, Rollema H: The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. Eur J Pharmacol. 2005 Jan 4;506(3):209-19. Epub 2004 Dec 15. [PubMed:15627430 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Reitz AB, Gupta SK, Huang Y, Parker MH, Ryan RR: The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. Med Chem. 2007 Nov;3(6):543-5. [PubMed:18045203 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23